🔗 Share this article

As the US continues making sweeping revisions to its immunization guidelines, one figure has emerged in a surprising turn: Høeg, a Danish American sports physician and public health researcher who rose to prominence by questioning coronavirus shots throughout the pandemic and has zeroed in on potential fatalities after COVID-19 vaccination in her brief time at the FDA.

Scheduled Shifts to Childhood Immunization Schedule

Health officials planned to reveal sweeping changes to the childhood vaccination calendar in December, bringing the US with Denmark’s vaccine program, it is understood – a major change that would put the US out of step with a large portion of the international standard with little proof for benefit. This reveal has been postponed until the coming year.

Instead of the director of the vaccine center, Tracy Beth Høeg is listed to speak at the gathering. She was just designated interim head of the FDA’s drug evaluation center, the fifth individual to run the division this calendar year.

A Shift at the Agency

Høeg's temporary position may indicate a closer partnership between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it signals a greater focus upon reevaluating already-approved immunizations at the FDA.

Dr. Høeg has frequently advocated for halting some pediatric vaccine recommendations in the US to become more like Denmark's approach, a country with universal health coverage and a number of inhabitants about the population of Wisconsin’s.

In her initial public appearances, she has kept her attention on immunizations – typically the purview of Dr. Prasad, chief of the FDA’s vaccine center – instead of medication approval.

Questions Over Background

Høeg has no apparent background in drug development, approval processes or management, which has been standard for former heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the commissioner and the vaccine center since spring.

“She appears not to have any of the qualifications” for leading the drug-regulation department, stated Jonathan Howard. “She lacks experience running a scientific study. She is not versed in managing a sizeable institution. She lacks background in industry regulation.”

Past commissioners of CBER would “grasp laws and regulations and the science of drug development”, noted Janet Woodcock. “Objectively, she has not acquired the sort of resume that former directors who led CBER have had.”

This division has an enormous workload at the agency, she stated.

“The public just focuses on the new drug program, but the generic drug division approves a multitude of generic drugs. There is also a biologic copycat branch, over-the-counter program and so forth, and every single one need to be looked after,” she noted. “The area you neglect, that is precisely what that I always told people is going to cause problems.”

Furthermore, a major administrative element to the position, which supervises in excess of 5,000 staff members. “It is a massive administrative position, if you do it right,” Woodcock concluded.

Response and Disputed Programs

In response to questions about Høeg’s qualifications and whether this assignment represents greater collaboration among agency officials on vaccines, a press secretary said that the “inquiries are based on inaccurate assumptions”.

“This background matches the responsibilities of her job,” the representative stated, citing the period Dr. Høeg spent advising the FDA commissioner on “medication safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As acting director, Høeg takes over the commissioner’s recently launched fast-track approval initiative, a controversial rapid therapy clearance system that apparently concerned her predecessors. “How are these drugs being chosen for this voucher program? Who makes the calls?” Dr. Howard questioned. “There is a lot of lack of transparency going on at the regulatory body right now.”

In general, he stated, “the FDA looks to be trending towards less stringent regulations of all drugs, aside from shots.”

Documented History on Vaccines

Concerning vaccines, Dr. Høeg has a more documented, if concerning, history, critics have noted. She released a study using non-validated public submissions to assess the incidence of myocarditis following Covid vaccination. She advised the state of Florida top health official Dr. Joseph Ladapo, who allegedly have altered data to suggest Covid vaccines are pose a greater threat than they are.

Included in her “desired changes” for the current government included altering guidelines for novel immunizations and ending “non-essential” immunizations, she said post-election on a audio program. At the agency, Høeg has reportedly floated the idea of preventing young men from obtaining COVID-19 vaccines.

“She is an thorough ideologue who commences with her beliefs and tailors the evidence to retrofit the evidence in a extremely deceptive, dishonest manner,” Howard stated.

Consolidating Power and a “Push for Payback”

Høeg became part of other skeptics, {like|